Osteoarthritis (OA) of the Knee
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
OrthoTrophixCA - Foster City
1 program1
TPX-100 200mg, Once weekly for 4 weeksPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
OrthoTrophixTPX-100 200mg, Once weekly for 4 weeks
Brixton BiosciencesNeural Ice
Clinical Trials (2)
Total enrollment: 533 patients across 2 trials
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
Start: May 2025Est. completion: Apr 2027270 patients
Phase 2Active Not Recruiting
INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE
Start: Nov 2024Est. completion: Feb 2027263 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.